Finalizing the design for its planned pivotal trial of cancer vaccine rindopepimut (CDX-110) in glioblastoma multiforme (GBM), slated to start in the second half of this year, Celldex Therapeutics Inc. padded its balance sheet with a $31.5 million public offering.